NCT03627143

Brief Summary

Acute atrial fibrillation and flutter (AAFF) is characterized by rapid heart rates with onset less than seven days. It's the most common type of palpitation treated in the Emergency Department (ED). Some Canadian ED's will discharge 95% of AAFF patients whereas others admit up to 40%. With hospital and ED crowding, discharge is the most optimal, effective and safe strategy. Our aim is to improve the care and reduce the length of stay (LOS) of ED AAFF patients, while decreasing unnecessary hospitalizations. First, the investigators must understand the local barriers. In the previous study, the investigators conducted interviews of emergency physicians, cardiologists and AAFF patients. In Project 1b, the investigators created the CAEP ED AAFF Guidelines Checklist to assist physicians to manage AAFF more efficiently and safely. The Guidelines are comprised of two algorithms and four sets of checklists for ED assessment and management. They have been endorsed by CAEP and are published in CJEM. The investigators are now planning Project 2 in which the investigators will conduct a cluster \[group\] randomized trial at 11 Canadian EDs and enroll 1,300 patients over thirteen months. The investigators are not randomizing individual patients or doctors; instead the investigators are randomizing the start date of individual hospitals. Our goal is to introduce the new Guidelines into these hospitals to improve the care of AAFF patients. The investigators hope to improve AAFF management, leading to a significant decrease in hospital admissions and ED LOS. Central to our plans will be engagement of our two patient partners. Our behaviorally optimized intervention will be developed using state-of-the-art implementation science approaches informed by the results of Project 1a. The investigators will also undertake within-project and end-of-project knowledge translation and implementation (KTI) strategies to facilitate scale up and roll out of our program to ED departments in small, medium, and large hospitals across Canada (future Project 3). Ultimately the investigators expect to improve ED practices and decrease AAFF admissions and LOS, without increasing visits.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
846

participants targeted

Target at P75+ for not_applicable atrial-fibrillation

Timeline
Completed

Started Sep 2018

Shorter than P25 for not_applicable atrial-fibrillation

Geographic Reach
1 country

12 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 19, 2018

Completed
25 days until next milestone

First Posted

Study publicly available on registry

August 13, 2018

Completed
19 days until next milestone

Study Start

First participant enrolled

September 1, 2018

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2019

Completed
Last Updated

June 21, 2021

Status Verified

June 1, 2021

Enrollment Period

1.1 years

First QC Date

July 19, 2018

Last Update Submit

June 18, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • length of stay in ED in minutes

    Length of stay in ED in min. from time of arrival to time of discharge or admission.

    a 100 minute reduction in ED length of stay (or a relative reduction of approximately 25%)

Secondary Outcomes (5)

  • Use of rhythm control in the ED

    13 months

  • Use of rate control and the final heart rate at disposition

    13 months

  • Appropriate prescription of anticoagulants on discharge

    1 day

  • Adverse events

    30 days from discharge from the ED

  • Return ED visits and admission

    30 days

Study Arms (1)

Local implementation of AAFF guidelines

OTHER

The study intervention will support local implementation of the CAEP AAFF Guidelines during the intervention periods of the trial. The investigators will identify behaviour change techniques and organization/system level strategies that could likely address identified barriers or enhance enablers.

Other: KTI activities

Interventions

The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients. 1. Selection of one or more local physician champions from both the ED as well as the cardiology group; 2. Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups; 3. Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources; 4. Development of local action plan addressing local barriers to implementation; 5. Provision of the free Smartphone App to be developed for the guidelines; 6. Regular reminders provided by the local research staff; 7. Audit and feedback charts of site compliance

Local implementation of AAFF guidelines

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • stable patients presenting with an episode of acute atrial fibrillation or flutter (AAFF) of at least 3 hours duration, where symptoms require ED management by rhythm or rate control.
  • patients with a history of prior episodes of AAFF, or those with previous presentations during the study periods.

You may not qualify if:

  • have permanent (chronic) AF
  • are deemed unstable and require immediate cardioversion: i) systolic blood pressure \<90 mmHg; ii) rapid ventricular pre-excitation (Wolff-Parkinson-White syndrome); iii) acute coronary syndrome - ongoing severe chest pain and marked ST depression (\>2mm) on ECG despite therapy; or iv) pulmonary edema - severe dyspnea requiring immediate IV diuretic, nitrates, or BIPAP;
  • the primary presentation was for another condition rather than arrhythmia
  • convert spontaneously to sinus rhythm prior to receiving physician-initiated therapy; or
  • die while in the ED from non-AAFF related causes.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

Dr. Georges-L. - Dumont University Hospital

Moncton, New Brunswick, Canada

Location

Dartmouth General Hospital

Dartmouth, Nova Scotia, Canada

Location

Ottawa Hospital

Ottawa, Ontario, K1Y 4E9, Canada

Location

St. Joseph's Health Center

Toronto, Ontario, Canada

Location

Hopital Du Sacre-Coeur

Montreal, Quebec, Canada

Location

Hôpital Charles-Lemoyne

Montreal, Quebec, Canada

Location

Hôpital Maisonneuve-Rosemont

Montreal, Quebec, Canada

Location

McGill University Health Centre

Montreal, Quebec, Canada

Location

Hôpital de l'Enfant-Jésus

Québec, Quebec, Canada

Location

Hôtel-Dieu de Lévis

Québec, Quebec, Canada

Location

Regina General Hospital

Regina, Saskatchewan, Canada

Location

Royal University Hospital

Saskatoon, Saskatchewan, Canada

Location

MeSH Terms

Conditions

Atrial FibrillationAtrial Flutter

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Ian Stiell, MD

    Ottawa Hospital Research Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: Multicentre Behaviour Intervention Trial using a Stepped Wedge Cluster Randomized Design
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 19, 2018

First Posted

August 13, 2018

Study Start

September 1, 2018

Primary Completion

September 30, 2019

Study Completion

October 30, 2019

Last Updated

June 21, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will not share

Locations